Imaging Results (MR Imaging and 18F-FET PET)
| 18F-FET-PET TBR | ||||||
| MR imaging | TBRmax | TBRmean | ||||
| Diagnosis | Contrast enhancement (n) | Lesion Mean ± SD (cm) | Mean ± SD | Range | Mean ± SD | Range |
| All (n = 174) | 76 (44%) | 4.3 ± 2.1 | 2.8 ± 1.3 | 1.0–7.5 | 1.8 ± 0.6 | 0.5–3.5 |
| NNLs (n = 25) | 9 (36%) | 3.3 ± 1.7 | 1.9 ± 0.5 | 1.0–2.5 | 1.4 ± 0.4 | 0.5–2.0 |
| Hematoma (n = 4) | 3 | 5.0 ± 1.8 | 1.9 ± 0.4 | 1.1–2.0 | 1.5 ± 0.4 | 1.1–1.9 |
| Demyelinating lesion (n = 5) | 2 | 2.9 ± 0.8 | 2.2 ± 0.8 | 1.0–2.3 | 1.6 ± 0.5 | 0.7–2.0 |
| Abscess (n = 6) | 2 | 3.5 ± 0.9 | 2.0 ± 0.5 | 1.3–2.6 | 1.5 ± 0.3 | 1.2–1.8 |
| Unspecific histology (n = 10) | 2 | 2.7 ± 2.1 | 1.6 ± 0.3 | 1.2–2.1 | 1.2 ± 0.4 | 0.5–1.7 |
| Neoplastic lesions (n = 149) | 67 (45%) | 2.9 ± 1.5 | 2.9 ± 1.3 | 1.0–7.5 | 1.9 ± 0.6 | 0.7–3.8 |
| Occult glioma (n = 4) | 1 | 2.6 ± 1.0 | 1.8 ± 0.7 | 1.5–2.4 | 1.4 ± 0.5 | 0.7–1.8 |
| Glioma WHO I (n = 4) | 2 | 2.4 ± 2.7 | 2.8 ± 1.9 | 1.0–3.8 | 1.7 ± 0.9 | 0.7–2.6 |
| Diffuse glioma WHO II (n = 73) | 18 (25%) | 4.5 ± 1.7 | 2.4 ± 1.0 | 1.0–5.2 | 1.6 ± 0.5 | 0.7–2.8 |
| Astrocytoma II (n = 53) | 13 | 4.8 ± 1.7 | 2.3 ± 0.9 | 1.0–5.1 | 1.6 ± 0.5 | 0.7–2.8 |
| Oligoastrocytoma II (n = 12) | 3 | 4.3 ± 1.5 | 2.7 ± 1.1 | 1.8–5.2 | 1.8 ± 0.4 | 1.1–2.6 |
| Oligodendroglioma II (n = 6) | 0 | 3.6 ± 1.3 | 2.6 ± 1.1 | 1.1–3.0 | 1.7 ± 0.5 | 0.9–2.2 |
| Ependymoma II (n = 2) | 2 | 1.5 ± 1.0 | 2.7 ± 1.1 | 1.9–3.5 | 1.9 ± 0.4 | 1.6–2.2 |
| Anaplastic glioma WHO III (n = 47) | 27 (57%) | 4.9 ± 2.5 | 3.5 ± 1.5 | 1.2–6.9 | 2.1 ± 0.7 | 0.7–3.8 |
| Astrocytoma III (n = 25) | 11 | 4.7 ± 2.5 | 3.3 ± 1.5 | 1.2–6.3 | 2.0 ± 0.7 | 0.7–3.8 |
| Oligoastrocytoma III (n = 11) | 8 | 6.0 ± 3.0 | 3.5 ± 1.4 | 1.3–5.4 | 2.0 ± 0.6 | 0.9–2.6 |
| Oligodendroglioma III (n = 11) | 8 | 4.3 ± 1.5 | 4.0 ± 1.4 | 2.2–6.9 | 2.3 ± 0.5 | 1.7–3.0 |
| Glioblastoma WHO IV (n = 19) | 18 (95%) | 3.7 ± 1.6 | 3.9 ± 1.2 | 2.6–7.5 | 2.3 ± 0.3 | 1.9–3.2 |
| Lymphoma (n = 2) | 1 | 6.7 ± 7.3 | 2.4 ± 0.7 | 1.9–2.9 | 1.8 ± 0.3 | 1.6–2.0 |